DK1301201T3 - Behandling af glycogenosis type II - Google Patents

Behandling af glycogenosis type II

Info

Publication number
DK1301201T3
DK1301201T3 DK01951000T DK01951000T DK1301201T3 DK 1301201 T3 DK1301201 T3 DK 1301201T3 DK 01951000 T DK01951000 T DK 01951000T DK 01951000 T DK01951000 T DK 01951000T DK 1301201 T3 DK1301201 T3 DK 1301201T3
Authority
DK
Denmark
Prior art keywords
treatment
glycogenosis type
storage disease
disease type
glycogen storage
Prior art date
Application number
DK01951000T
Other languages
Danish (da)
English (en)
Inventor
Yuan-Tsong Chen
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1301201(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of DK1301201T3 publication Critical patent/DK1301201T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK01951000T 2000-07-18 2001-07-10 Behandling af glycogenosis type II DK1301201T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
PCT/US2001/021651 WO2002005841A1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii

Publications (1)

Publication Number Publication Date
DK1301201T3 true DK1301201T3 (da) 2007-04-02

Family

ID=22818451

Family Applications (5)

Application Number Title Priority Date Filing Date
DK18194771.4T DK3449934T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK07001091.3T DK1782825T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK14167882.1T DK2767291T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II
DK01951000T DK1301201T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenosis type II
DK16178390.7T DK3108895T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK18194771.4T DK3449934T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK07001091.3T DK1782825T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK14167882.1T DK2767291T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16178390.7T DK3108895T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II

Country Status (18)

Country Link
US (10) US7056712B2 (de)
EP (4) EP3449934B1 (de)
JP (10) JP5113312B2 (de)
AT (1) ATE355075T1 (de)
AU (3) AU2001271941B2 (de)
BR (1) BR0113006A (de)
CA (1) CA2416492C (de)
CY (2) CY1120977T1 (de)
DE (1) DE60126947T2 (de)
DK (5) DK3449934T3 (de)
ES (5) ES2799882T3 (de)
HK (3) HK1054690A1 (de)
LT (3) LT2767291T (de)
MX (1) MXPA03000474A (de)
PT (5) PT3108895T (de)
SI (3) SI2767291T1 (de)
TW (1) TWI280882B (de)
WO (1) WO2002005841A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2799882T3 (es) * 2000-07-18 2020-12-22 Univ Duke Tratamiento de glucogenosis de tipo II
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2004064750A2 (en) * 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
WO2005078077A2 (en) * 2004-02-10 2005-08-25 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CA2568150A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
AU2007322123A1 (en) * 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
WO2009137721A2 (en) * 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
DK2318037T3 (en) 2008-07-08 2015-05-04 Univ Duke Method for treating a glycogen storage-DISEASE
US8785168B2 (en) * 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011139379A2 (en) 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
WO2014130723A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
CA2912678C (en) * 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
CA3228032A1 (en) 2014-09-30 2016-04-07 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
WO2016178431A1 (ja) * 2015-05-07 2016-11-10 国立大学法人 東京大学 ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法
US20180326021A1 (en) * 2015-08-31 2018-11-15 Duke University Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
KR20230041833A (ko) 2015-12-30 2023-03-24 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
SG11201808592PA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Method for selection of high m6p recombinant proteins
KR20230125339A (ko) 2016-04-15 2023-08-29 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
AU2018335752A1 (en) 2017-09-22 2020-03-12 Christian HINDERER Gene therapy for treating Mucopolysaccharidosis type ii
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
IL139616A0 (en) 1998-05-13 2002-02-10 Harbor Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof
DK2020438T3 (en) 1998-12-07 2018-07-23 Genzyme Corp Treatment of Pompe disease
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
ES2799882T3 (es) * 2000-07-18 2020-12-22 Univ Duke Tratamiento de glucogenosis de tipo II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2005078077A2 (en) * 2004-02-10 2005-08-25 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
US20120058132A1 (en) 2012-03-08
AU2001271941B2 (en) 2007-03-01
DK1782825T3 (da) 2014-11-03
JP2018002749A (ja) 2018-01-11
DE60126947T2 (de) 2007-10-31
BR0113006A (pt) 2004-10-19
US7056712B2 (en) 2006-06-06
EP1301201A1 (de) 2003-04-16
JP5792774B2 (ja) 2015-10-14
EP3449934A1 (de) 2019-03-06
JP2017137357A (ja) 2017-08-10
US8900552B2 (en) 2014-12-02
PT3108895T (pt) 2018-12-18
CA2416492A1 (en) 2002-01-24
DE60126947D1 (de) 2007-04-12
WO2002005841A1 (en) 2002-01-24
JP6163216B2 (ja) 2017-07-12
LT3449934T (lt) 2020-08-10
SI3108895T1 (sl) 2019-01-31
SI2767291T1 (sl) 2016-11-30
PT1301201E (pt) 2007-03-30
EP3108895B1 (de) 2018-09-19
MXPA03000474A (es) 2003-10-06
US20100254966A1 (en) 2010-10-07
PT2767291T (pt) 2016-10-25
CY1123084T1 (el) 2021-10-29
DK3108895T3 (en) 2018-11-26
HK1197656A1 (zh) 2015-02-06
AU7194101A (en) 2002-01-30
DK2767291T3 (en) 2016-12-05
JP2016056206A (ja) 2016-04-21
US9370556B2 (en) 2016-06-21
EP3108895A1 (de) 2016-12-28
US20180185457A1 (en) 2018-07-05
JP2020019822A (ja) 2020-02-06
CY1120977T1 (el) 2019-12-11
JP2012006953A (ja) 2012-01-12
ES2599401T3 (es) 2017-02-01
EP3449934B1 (de) 2020-05-20
HK1103363A1 (en) 2007-12-21
US9907839B2 (en) 2018-03-06
EP1301201B1 (de) 2007-02-28
CA2416492C (en) 2008-04-29
SI3449934T1 (sl) 2020-09-30
ES2523024T3 (es) 2014-11-20
ATE355075T1 (de) 2006-03-15
PT1782825E (pt) 2014-11-04
US20050123531A1 (en) 2005-06-09
HK1054690A1 (en) 2003-12-12
EP2767291A2 (de) 2014-08-20
JP2004503598A (ja) 2004-02-05
ES2277931T3 (es) 2007-08-01
DK3449934T3 (da) 2020-06-29
ES2799882T3 (es) 2020-12-22
JP2014185187A (ja) 2014-10-02
JP2018199721A (ja) 2018-12-20
ES2700865T3 (es) 2019-02-19
AU2010200487A1 (en) 2010-03-04
US20160184410A1 (en) 2016-06-30
JP2013231081A (ja) 2013-11-14
TWI280882B (en) 2007-05-11
EP2767291A3 (de) 2014-10-08
JP2008081507A (ja) 2008-04-10
PT3449934T (pt) 2020-06-25
US20130195834A1 (en) 2013-08-01
JP5113312B2 (ja) 2013-01-09
US20150004152A1 (en) 2015-01-01
LT3108895T (lt) 2018-11-26
US10792341B2 (en) 2020-10-06
EP2767291B1 (de) 2016-09-14
US20020110551A1 (en) 2002-08-15
US20210169996A1 (en) 2021-06-10
LT2767291T (lt) 2016-11-25
US20080175833A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
EA200201214A1 (ru) Замещенные тиоацетамиды
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
ATE245152T1 (de) Dioxocyclopentylhydroxamsäure
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
WO2003063787A3 (en) Non-steroidal analogs of 2-methoxyestradiol
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
SE0003476D0 (sv) Compounds
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
EA200501164A1 (ru) Индазоламиды с аналгетической активностью
NO20053876L (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE502639T1 (de) 4-hydroxypiperidin-derivate zur verwendung als antimycobakterielle mittel
CY1118235T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ii